Trinity Biotech (TRIB) Capital Expenditures (2009 - 2024)

Trinity Biotech has disclosed Capital Expenditures across 6 years of filings, most recently posting -$157000.0 for Q4 2024.

• Capital Expenditures for Q4 2024 came in at -$157000.0, up 37.2% year-over-year; the trailing twelve-month figure through Dec 2024 was -$1.0 million (up 13.97% YoY), and the FY2025 annual result was $88000.0, down 78.27% from the prior year.
• Capital Expenditures came in at -$157000.0 for Q4 2024 at Trinity Biotech, up from -$250000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of -$143.0 in Q2 2022 to a low of -$570000.0 in Q4 2021.
• The 4-year median for Capital Expenditures is -$203500.0 (2023), against an average of -$237691.5.
• Peak annual rise in Capital Expenditures reached 63.24% in 2022, while the deepest fall reached 16.67% in 2022.
• Trinity Biotech's Capital Expenditures stood at -$570000.0 in 2021, then grew by 16.67% to -$475000.0 in 2022, then surged by 47.37% to -$250000.0 in 2023, then surged by 37.2% to -$157000.0 in 2024.
• The last three Capital Expenditures figures came in at -$157000.0 (Q4 2024), -$250000.0 (Q4 2023), and -$128000.0 (Q3 2023), per Business Quant data.